AP-HP, Salpêtrière Hospital, University of Pierre & Marie Curie Paris 6, Medical Oncology Department, 47 boulevard de l'Hôpital, Paris, France.
Crit Rev Oncol Hematol. 2010 Apr;74(1):27-39. doi: 10.1016/j.critrevonc.2009.08.005. Epub 2009 Sep 24.
The number of melanoma cases worldwide is increasing faster than any other cancer and remains one of the most treatment-refractory malignancies. Despite decades of clinical trials testing chemotherapy and immunotherapy, a standard first-line treatment for metastatic melanoma has not yet been established; tough single agent dacarbazine represents the most common option. This review will focus on metastatic malignant melanoma treatment from single agent until new therapies. An overview of established chemotherapies and immunotherapies, followed by a summary of trials testing the potential combination and new agent are explored.
全球范围内黑色素瘤的发病人数增长速度超过其他任何癌症，且仍然是最难治疗的恶性肿瘤之一。尽管数十年来的临床试验已经测试了化疗和免疫疗法，但尚未确定转移性黑色素瘤的标准一线治疗方法；艰难的单一药物达卡巴嗪是最常见的选择。这篇综述将重点关注从单一药物治疗到新疗法的转移性恶性黑色素瘤治疗。概述了已确立的化疗和免疫疗法，随后总结了潜在联合用药和新药的试验情况。
